PerkinElmer receives EUA for respiratory SARS-CoV-2 panel

By LabPulse.com staff writers

October 7, 2021 -- PerkinElmer has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its PKamp Respiratory SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) Panel 1.

Qualified laboratories can immediately begin using the RT-PCR test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs, and midturbinate swabs, the company said.

The PKamp Respiratory assay allows laboratories to conserve resources by avoiding multiple tests on samples collected from individuals suspected of respiratory viral infection consistent with COVID-19, PerkinElmer said.

FDA grants EUA for Visby Medical's COVID-19 test
The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) for Visby Medical's COVID-19 reverse transcription polymerase...
COVID-19 tests attempt to prove at-home testing concept can work
More than a year into the pandemic, at-home COVID-19 testing remains stable, and the healthcare industry continues to develop new tests, according to...
Thermo Fisher secures EUA for 2 new COVID-19 tests
The U.S. Food and Drug Administration has granted emergency use authorization (EUA) to Thermo Fisher Scientific for two new COVID-19 tests, TaqPath COVID-19...
Qiagen receives EUA for portable SARS-CoV-2 antigen test
Qiagen announced it has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its QIAreach SARS-CoV-2 digital assay,...
NanoDx inks deal with IBM, seeks EUA for COVID-19 test
NanoDx announced that it has signed a licensing deal with IBM Research and will pursue an emergency use authorization (EUA) from the U.S. Food and Drug...

Copyright © 2021 LabPulse.com

Last Updated ls 10/7/2021 4:55:40 PM